What are the policies for charity assistance applications for imatinib?

Imatinib/Gleevec (Imatinib) is a tyrosine kinase inhibitor widely used to treat some hematological and solid tumors related to genetic mutations. Its main indications include Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) and KIT-positive gastrointestinal stromal tumor (GIST). In addition, imatinib is also used to treat other malignant tumors, such as synthetic leukemia, eosinophilic leukemia, etc. Due to its good targeting and relatively low side effects, imatinib has become a standard treatment for patients with these diseases.

For chronic myelogenous leukemia (CML), imatinib controls the proliferation of leukemia cells by inhibiting the tyrosine kinase activity of the BCR-ABL fusion protein and significantly improves the survival of patients. In the treatment of gastrointestinal stromal tumors (GIST), imatinib reduces tumor growth and metastasis by targeting the KIT receptor. Therefore, the therapeutic effect of imatinib on these patients has been widely recognized.

In addition to its remarkable therapeutic effects, the high price of imatinib may impose a financial burden on some patients. To this end, drug manufacturers, charities and government departments in many countries and regions have launched a variety of charitable assistance projects and policies to help patients obtain the drugs they need.

In the United States, Novartis, the maker of Gleevec (Imatinib), offers a patient assistance program that provides free imatinib to low-income patients who cannot afford the drug. Through this program, eligible patients can apply to receive free medications. In addition, Novartis partners with several non-profit organizations to help patients solve access to medicines. For some patients not covered by insurance, subsidies for drug costs and drug delivery services will help them continue treatment.

Reference materials:https://www.gleevec.com/